Search

Displaying results 3321 - 3330 of 7687 in total
  1. Drug

    Caroxazone

    go.drugbank.com/drugs/DB09254
    ApprovedWithdrawn

    Caroxazone is an antidepressant that has been withdrawn from the market. It is a reversible monoamine oxidase inhibitor (MAOI) of both A and B monoamine oxidase subtypes.

  2. Drug

    Ropivacaine

    go.drugbank.com/drugs/DB00296
    ApprovedInvestigational

    Ropivacaine is an aminoamide local anesthetic drug marketed by AstraZeneca under the trade name Naropin.

  3. Drug

    CM4620

    go.drugbank.com/drugs/DB16466
    Investigational

    CM4620 (Zegocractin), is under investigation in multiple clinical trials, including NCT04195347 (pancreatitis due to asparaginase), NCT03709342 (PK/PD study in acute pancreatitis), NCT03401190 and NCT04681066

    Synonyms: N-(5-(6-CHLORO-2,2-DIFLUOROBENZO(D)(1,3)DIOXOL-5-YL)PYRAZIN-2-YL)-2-FLUORO-6-METHYLBENZAMIDE
  4. Drug

    Benzylfentanyl

    go.drugbank.com/drugs/DB09182
    ExperimentalIllicit

    Benzylfentanyl (R-4129) is a fentanyl analog opioid that was on the list of Schedule I drugs in America in 1985 due to its structural similarity to fentanyl. … Benzylfentanyl has a Ki of 213nM at the mu opioid receptor, binding around 200x less strongly than fentanyl itself.

  5. Drug

    Rimonabant

    go.drugbank.com/drugs/DB06155
    ApprovedWithdrawn

    Rimonabant is an anorectic anti-obesity drug produced and marketed by Sanofi-Aventis. It is an inverse agonist for the cannabinoid receptor CB1. Its main avenue of effect is reduction in appetite.

  6. Drug

    R1295

    go.drugbank.com/drugs/DB05122
    Experimental

    R1295 is an integrin antagonist currently in clinical trials for the treatment of rheumatoid arthritis.

  7. Drug

    Seletracetam

    go.drugbank.com/drugs/DB05885
    Investigational

    As of 2010, its production was further halted due to the investigation of a newer antiepileptic agent, brivaracetam. … Food and Drug Administration (FDA) investigated as treatment of epilepsy and partial epilepsy however its development had been put on hold in July 2007.

  8. Drug

    JSM 6427

    go.drugbank.com/drugs/DB06139
    Investigational

    JSM 6427 is the first small molecule alpha5beta1 integrin receptor antagonist of its kind to be developed. It has been biologically validated for therapeutic use in the prevention and treatment of wet AMD, the leading cause of blindness ...

  9. Drug

    Gliclazide

    go.drugbank.com/drugs/DB01120
    ApprovedInvestigational

    Gliclazide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). … Due to their mechanism of action, sulfonylureas may cause hypoglycemia and require consistent food intake to decrease this risk.

    Products: Nu-gliclazide
  10. Drug

    Amilomotide

    go.drugbank.com/drugs/DB05150
    Investigational

    CAD106 is an immunotherapeutic product in development for the treatment of Alzheimer's disease.